Opinion|Videos|January 5, 2024
Adverse Events Seen With JAK Inhibitors for Myelofibrosis
Author(s)Christine Cooper, RN, BSN, Aaron Gerds, MD, MS
The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on CURE
1
‘Full House’ Star Dave Coulier Talks Tongue Cancer Diagnosis
2
New Approach May Offer Stronger Treatment Effects in Metastatic Breast Cancer
3
Dave Coulier Embraces Positivity Amid a Second Cancer Diagnosis
4
How Modern Research Is Transforming Metastatic HER2+ Breast Cancer Care
5